Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Rituximab
Drug: Sapacitabine

First Posted Date: 2010-12-03

Last Posted Date: 2019-09-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT01253460

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase l/II Study of Ruxolitinib for Acute Leukemia

Phase 1

Terminated

Conditions: Leukemia

Interventions: Drug: Ruxolitinib

First Posted Date: 2010-12-02

Last Posted Date: 2025-06-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT01251965

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: AZD6244
Drug: Erlotinib
Drug: Sorafenib
Drug: MK-2206

First Posted Date: 2010-11-25

Last Posted Date: 2022-01-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 334

Registration Number: NCT01248247

Locations: 🇺🇸
Yale Universtiy, New Haven, Connecticut, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Adenocarcinoma
Ductal Breast Carcinoma In Situ
Stage IA Breast Cancer AJCC v7
Stage II Breast Cancer AJCC v6 and v7
Stage IIA Breast Cancer AJCC v6 and v7
Stage 0 Breast Cancer AJCC v6 and v7
Stage I Breast Cancer AJCC v7
Stage IB Breast Cancer AJCC v7
Invasive Breast Carcinoma
Stage IIB Breast Cancer AJCC v6 and v7

Interventions: Radiation: Accelerated Partial Breast Irradiation
Radiation: Proton Beam Radiation Therapy
Other: Quality-of-Life Assessment

First Posted Date: 2010-11-22

Last Posted Date: 2025-06-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT01245712

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Ofatumumab

First Posted Date: 2010-11-18

Last Posted Date: 2023-04-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT01243190

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Phase 2

Completed

Conditions: Myeloma

Interventions: Drug: Palifermin
Drug: Dexamethasone
Drug: Gemcitabine
Drug: Busulfan
Drug: Melphalan
Procedure: Stem Cell Transplant
Drug: G-CSF

First Posted Date: 2010-11-10

Last Posted Date: 2020-05-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 75

Registration Number: NCT01237951

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble

Phase 3

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Procedure: Perfusion CT scan

First Posted Date: 2010-10-20

Last Posted Date: 2025-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT01224288

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: Lenalidomide
Drug: Darbepoetin alfa

First Posted Date: 2010-10-18

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01222195

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Symptom Burden in Head and Neck Cancer

Phase 1

Terminated

Conditions: Head And Neck Cancer

Interventions: Other: Placebo
Drug: Armodafinil
Drug: Bupropion
Drug: Minocycline

First Posted Date: 2010-10-13

Last Posted Date: 2015-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01219673

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Trimodality Management of T1b Esophageal Cancers

Phase 1

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Docetaxel
Drug: 5-FU
Radiation: Radiotherapy
Procedure: Esophagectomy
Drug: Dexamethasone

First Posted Date: 2010-10-08

Last Posted Date: 2021-04-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT01217060

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy